BCHE and Alzheimer disease: The 3- to 5-point difference across 18 months of trial duration is 2 to 3 times the differences planned in the current clinical trials of experimental drugs for mild or moderate dementia due to AD for early AD trials [1, 3, 4, 24], or the actual difference in marketed cholinesterase inhibitors trials compared with placebo [25, 26].